N/A
N=50
Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
Function of Renal Transplant
Bottom Line
View on ClinicalTrials.gov: NCT01759862 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Aminophylline (Drug); Theophylline drug levels (Other); Placebo (Drug)
- Age
- Pediatric, Adult · 1+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Calculated Estimated Glomerular Filtration Rate (eGFR) |
67.39; 80.48 | 0.32 |
| SECONDARY Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin)/ Creatinine Ratio |
300.5; 425.4 | 0.95 |
Summary
The aim of this study is to evaluate whether peri-transplant administration of a drug named aminophylline to children undergoing a kidney transplant from deceased donors improves early graft function and also projects on long term graft function.
Eligibility Criteria
Inclusion Criteria
- Pediatric kidney transplant recipients less than 21 years of age
- Patients undergoing deceased donor (DD) kidney transplants
Exclusion Criteria
- Known history of non-sinus tachycardia
- Multiple organ transplants recipients
- Severe liver dysfunction
- graft was placed on pump after harvesting
Data sourced from ClinicalTrials.gov (NCT01759862). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.